Sophie Trouillet-Assant

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/688688/publications.pdf

Version: 2024-02-01

37 papers

4,043 citations

20 h-index

361413

330143 37 g-index

42 all docs 42 docs citations

42 times ranked

8993 citing authors

#	Article	IF	CITATIONS
1	Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs. Science Immunology, 2023, 8, .	11.9	35
2	Evaluation of Commercial Anti-SARS-CoV-2 Antibody Assays and Comparison of Standardized Titers in Vaccinated Health Care Workers. Journal of Clinical Microbiology, 2022, 60, JCM0174621.	3.9	32
3	Are Anti-Receptor–Binding Domain Antibodies Still a Relevant Proxy for Monitoring SARS-CoV-2 Neutralizing Activity in the Omicron Era?. Clinical Chemistry, 2022, 68, 984-986.	3.2	3
4	Evaluation of commercial Anti-SARS-CoV-2 neutralizing antibody assays in seropositive subjects. Journal of Clinical Virology, 2022, 152, 105169.	3.1	10
5	The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2200413119.	7.1	110
6	Typeâ€l Interferon assessment in 45 minutes using the FilmArray [®] PCR platform in SARSâ€CoVâ€2 and other viral infections. European Journal of Immunology, 2021, 51, 989-994.	2.9	4
7	Evaluation of High-Throughput SARS-CoV-2 Serological Assays in a Longitudinal Cohort of Patients with Mild COVID-19: Clinical Sensitivity, Specificity, and Association with Virus Neutralization Test. Clinical Chemistry, 2021, 67, 742-752.	3.2	69
8	Antibodies against type I interferon: detection and association with severe clinical outcome in COVIDâ€19 patients. Clinical and Translational Immunology, 2021, 10, e1327.	3.8	79
9	Live virus neutralization testing in convalescent patients and subjects vaccinated against 19A, 20B, 20I/501Y.V1 and 20H/501Y.V2 isolates of SARS-CoV-2. Emerging Microbes and Infections, 2021, 10, 1499-1502.	6.5	9
10	Polyclonal expansion of TCR $\hat{Vl^2}$ 21.3 ⁺ CD4 ⁺ and CD8 ⁺ T cells is a hallmark of multisystem inflammatory syndrome in children. Science Immunology, 2021, 6, .	11.9	105
11	Differential response induced by LPS and MPLA in immunocompetent and septic individuals. Clinical Immunology, 2021, 226, 108714.	3.2	9
12	Six-month antibody response to SARS-CoV-2 in healthcare workers assessed by virus neutralization and commercial assays. Clinical Microbiology and Infection, 2021, 27, 933-935.	6.0	13
13	Clinical and laboratory characteristics of symptomatic healthcare workers with suspected COVID-19: a prospective cohort study. Scientific Reports, 2021, 11, 14977.	3.3	13
14	Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs. Journal of Experimental Medicine, 2021, 218, .	8.5	85
15	Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Science Immunology, 2021, 6, .	11.9	357
16	Characterization of SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster during routine genomic surveillance, Lyon, France. Emerging Microbes and Infections, 2021, 10, 167-177.	6.5	32
17	lmmunogenicity and efficacy of          heterologous ChAdOx1–BNT162b2 vaccination 701-706.	on. Nature, 27.8	, 2021, 600, 180
18	Towards standardization of immune functional assays. Clinical Immunology, 2020, 210, 108312.	3.2	8

#	Article	IF	Citations
19	Torque Teno Virus Viral Load as a Marker of Immune Function in Allogeneic Haematopoietic Stem Cell Transplantation Recipients. Viruses, 2020, 12, 1292.	3.3	23
20	Assessment of serological techniques for screening patients for COVID-19 (COVID-SER): a prospective, multicentric study. BMJ Open, 2020, 10, e041268.	1.9	19
21	Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Human Airway Epithelia. Cell Reports Medicine, 2020, 1, 100059.	6.5	188
22	Deciphering heterogeneity of septic shock patients using immune functional assays: a proof of concept study. Scientific Reports, 2020, 10, 16136.	3.3	11
23	Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science, 2020, 370, .	12.6	1,983
24	Type I Interferon in Children with Viral or Bacterial Infections. Clinical Chemistry, 2020, 66, 802-808.	3.2	13
25	Type I IFN immunoprofiling in COVID-19 patients. Journal of Allergy and Clinical Immunology, 2020, 146, 206-208.e2.	2.9	234
26	Metagenomic Next-Generation Sequencing Reveals Individual Composition and Dynamics of Anelloviruses during Autologous Stem Cell Transplant Recipient Management. Viruses, 2018, 10, 633.	3.3	23
27	Immune Functional Assays, From Custom to Standardized Tests for Precision Medicine. Frontiers in Immunology, 2018, 9, 2367.	4.8	61
28	Understanding the Virulence of Staphylococcus pseudintermedius: A Major Role of Pore-Forming Toxins. Frontiers in Cellular and Infection Microbiology, 2018, 8, 221.	3.9	37
29	Pathophysiological Mechanisms of Staphylococcus Non-aureus Bone and Joint Infection: Interspecies Homogeneity and Specific Behavior of S. pseudintermedius. Frontiers in Microbiology, 2016, 7, 1063.	3.5	31
30	Human Monocyte-Derived Osteoclasts Are Targeted by Staphylococcal Pore-Forming Toxins and Superantigens. PLoS ONE, 2016, 11, e0150693.	2.5	19
31	Adaptive processes of (i) Staphylococcus aureus (i) isolates during the progression from acute to chronic bone and joint infections in patients. Cellular Microbiology, 2016, 18, 1405-1414.	2.1	47
32	Methicillin-susceptible strains responsible for postoperative orthopedic infection are not selected by the use of cefazolin in prophylaxis. Diagnostic Microbiology and Infectious Disease, 2016, 84, 266-267.	1.8	4
33	Mupirocin Resistance in Isolates of Staphylococcus spp. from Nasal Swabs in a Tertiary Hospital in France. Journal of Clinical Microbiology, 2015, 53, 2713-2715.	3.9	16
34	Evaluation of the BD GeneOhm Methicillin-Resistant Staphylococcus aureus (MRSA) Assay as a Method for Detection of MRSA Isolates, Using a Large Collection of European and North African Isolates. Journal of Clinical Microbiology, 2014, 52, 4372-4374.	3.9	0
35	Ward-Specific Rates of Nasal Cocolonization with Methicillin-Susceptible and -Resistant Staphylococcus spp. and Potential Impact on Molecular Methicillin-Resistant Staphylococcus aureus Screening Tests. Journal of Clinical Microbiology, 2013, 51, 2418-2420.	3.9	7
36	PSMs of Hypervirulent Staphylococcus aureus Act as Intracellular Toxins That Kill Infected Osteoblasts. PLoS ONE, 2013, 8, e63176.	2.5	103

#	Article	IF	CITATIONS
37	Staphylococcus epidermidis in Orthopedic Device Infections: The Role of Bacterial Internalization in Human Osteoblasts and Biofilm Formation. PLoS ONE, 2013, 8, e67240.	2.5	65